Tocilizumab versus sarilumab among adults hospitalised with COVID-19: target trial emulation across England and Scotland

Abstract The interleukin-6 (IL-6) inhibitors tocilizumab and sarilumab have been repurposed for COVID-19 treatment. However, discrepancies exist across global and national COVID-19 guidelines, with limited data on the comparative effectiveness between these therapeutics especially during the delta/o...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Bang Zheng, Amanj Kurdi, Alain Amstutz, Amelia Green, Emily Herrett, John Tazare, Qing Wen, Viyaasan Mahalingasivam, Rebecca Smith, Brian MacKenna, Amir Mehrkar, Seb Bacon, Ben Goldacre, Chris Robertson, Sir Aziz Sheikh, Laurie Tomlinson, On behalf of The OpenSAFELY Collaborative
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Nature Portfolio 2026-05-01
Schriftenreihe:	Nature Communications
Online-Zugang:	https://doi.org/10.1038/s41467-026-73134-9
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!